Premier Biomedical

Premier Biomedical, a research-based firm, develops medical products for Alzheimer’s disease, traumatic brain injury, and more.

Premier Biomedical, Inc. has acquired exclusive licenses for patent-pending medications/medical procedures to develop cures for a significant number of the most debilitating and often fatal illnesses affecting mankind: Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), Multiple Sclerosis (MS), Clinical Depression, Alzheimer’s Disease, Blood Sepsis, Atherosclerosis and Cancer. We have developed an aggressive timetable to advance the development of these breakthrough technologies through laboratory, hospital, and clinical trials. We have initiated the development of potential patient trial application lists. We have a management team with extensive experience and contacts in the medical/pharmaceutical fields as well as a demonstrated track record of launching new business ventures in a competitive environment. Our extensive contacts in the medical/pharmaceutical industries will ensure that new developments will achieve maximum visibility and exposure to the market. Transparency and accountability will continue to be ensured via regular issuance of technical progress reports, financials, and investor relations reports to maintain investor enthusiasm. Premier Biomedical, Inc., a Nevada corporation, is a fully reporting issuer under the Securities Exchange Act of 1934, listed under “BIEI” on the OTC-BB Index.